<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956811</url>
  </required_header>
  <id_info>
    <org_study_id>2015DM07</org_study_id>
    <secondary_id>2016-000715-33</secondary_id>
    <nct_id>NCT02956811</nct_id>
  </id_info>
  <brief_title>Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?</brief_title>
  <acronym>DAPA-LVH</acronym>
  <official_title>DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Tayside</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Left ventricular hypertrophy (LVH) is common in people with type 2 diabetes (70%) and is the&#xD;
      strongest independent risk factor for cardiovascular events and all-cause mortality that&#xD;
      there is. It is worse than triple vessel coronary disease. LVH often occurs in patients with&#xD;
      &quot;normal&quot; blood pressures (BP). Apart from BP, the other three main factors causing LVH are&#xD;
      insulin resistance, obesity and cardiac preload. Dapagliflozin reduces ALL four factors known&#xD;
      to promote LVH i.e. Dapagliflozin reduces weight, glycaemia, preload and blood pressure and&#xD;
      is therefore the ideal agent to reduce LVH since it uniquely attacks all four known mediators&#xD;
      of LVH. This trial will investigate the ability of dapagliflozin to regress LVH in 64&#xD;
      participants with normotensive diabetes. This will be done by seeing if dapagliflozin reduces&#xD;
      left ventricular mass as measured by cardiac magnetic resonance imaging (MRI). This trial may&#xD;
      identify a novel way to reduce the strong independent risk factor of LVH which often persists&#xD;
      despite optimum medical therapy in patients with diabetes. If dapagliflozin does reduce LVH,&#xD;
      this would be a key sign of which subgroup of patients with diabetes (those with LVH) should&#xD;
      be especially targeted with dapagliflozin.&#xD;
&#xD;
      64 participants with type 2 diabetes and LVH will be recruited through the Scottish Diabetes&#xD;
      Research Network (SDRN), Scottish Primary Care Research Network (SPCRN) and other routes, in&#xD;
      this single centre study. Participants will be randomised to receive either 10mg&#xD;
      dapagliflozin or placebo daily for 12 months. Cardiac MRI will be performed at baseline and&#xD;
      at 12 months, this will be assessed for the primary outcome of change in left ventricular&#xD;
      mass. Secondary outcomes will examine change in 24 hour blood pressure and weight.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Left ventricular hypertrophy (LVH) is present in the majority of patients with type 2&#xD;
      diabetes, since it affects 70%. It is a strong independent predictor of cardiovascular deaths&#xD;
      and events and is even worse than triple vessel coronary disease. The reason why LVH is so&#xD;
      adverse is because it predates so many different cardiovascular events i.e. LVH is&#xD;
      intrinsically arrhythmogenic and causes sudden death, it impedes left ventricular (LV)&#xD;
      filling and leads to diastolic heart failure, it reduces coronary perfusion reserve and&#xD;
      causes ischaemia and it causes left atrial enlargement, atrial fibrillation (AF), and&#xD;
      cardio-embolic strokes. Controlling blood pressure (BP) and using a drug that blocks the&#xD;
      renin-angiotensin system (RAS) are the standard approaches to the management of LVH but this&#xD;
      approach is only partially effective since 44% of all patients with type 2 diabetes are&#xD;
      normotensive patients with LVH. Thus &quot;normotensive LVH&quot; is very common. Indeed, BP only&#xD;
      contributes 25% to the variability in LV mass seen in a population. (This is important since&#xD;
      LVH is the same thing as a high level of LV mass). Despite a &quot;normal&quot; BP, normotensive LVH is&#xD;
      just as risky as is hypertensive LVH. Nevertheless, we do know that regressing LVH&#xD;
      irrespective of BP changes is an effective way to reduce the incidence of all major&#xD;
      cardiovascular (CV) events including specifically sudden deaths, heart failure&#xD;
      hospitalisations, new onset AF and strokes. The Losartan Intervention For Endpoint reduction&#xD;
      in hypertension study (LIFE) provides conclusive proof that in diabetes, LVH regression per&#xD;
      se reduces future cardiovascular events (by 24%), reduces CV deaths (by 37%) and reduces&#xD;
      total deaths (by 41%) irrespective of BP.&#xD;
&#xD;
      Since controlling BP and using an angiotensin enzyme inhibitor or angiotensin receptor&#xD;
      blocker is only partially effective at regressing LVH, additional ways of regressing LVH are&#xD;
      now required. Insulin resistance is another mediator of LVH. The literature is awash with&#xD;
      observational studies linking insulin resistance to LVH. Pub Med identifies 67 such papers, 5&#xD;
      of which are inconclusive. In the remaining 62 papers, 46 identify a significant relationship&#xD;
      between LVH and some measure of insulin resistance while 16 found no such relationship. The&#xD;
      large studies are mostly positive which includes Framingham, the Whitehall trial, the Strong&#xD;
      Heart trial and the Women's Health Initiative trial while the Hypertension Genetic&#xD;
      Epidemiology Network (HyperGEN) trial is the one large negative trial. There are a multitude&#xD;
      of mechanisms whereby hyperinsulinaemia should produce LVH e.g. through signalling pathways&#xD;
      such as Akt, transforming growth factor and peroxisome proliferator-activated receptors,&#xD;
      through increased myocardial free fatty acid oxidation and through RAS activation causing&#xD;
      sodium retention and thus increased cardiac preload. Therefore, it is likely that glycaemia&#xD;
      contributes to LVH. However, reducing glycaemia per se appears to be insufficient to reduce&#xD;
      CV events and key ancillary properties of each anti-glycaemic drug will be necessary to&#xD;
      deliver the CV benefits we so badly need in diabetes.&#xD;
&#xD;
      A separate albeit related factor mediating LVH is obesity. Importantly, dapagliflozin has&#xD;
      been shown to reduce weight. Thus the ideal treatment to regress LVH might be one that not&#xD;
      only improves glycaemia but one that also aids weight loss. Dapagliflozin is the obvious&#xD;
      option here since it has been shown to reduce both glycaemia and weight. Metformin is the&#xD;
      only other anti-glycaemic which reduces both glycaemia and weight. Indeed the reason&#xD;
      metformin reduces CV events in diabetes while other anti-glycaemic agents do not could well&#xD;
      be in part because metformin reduces both glycaemia and weight which then reduce LVH (in fact&#xD;
      we already have a separate British Heart Foundation grant to see if metformin really does&#xD;
      reduce LV mass).&#xD;
&#xD;
      However dapagliflozin has other unique effects on the CV system which will impact on LVH.&#xD;
      Dapagliflozin reduces blood pressure (LV afterload) and this by itself should also further&#xD;
      reduce LVH. Further reducing BP even in normotensive patients has been shown to definitely&#xD;
      regress LVH. Dapagliflozin also has diuretic effects which should reduce preload on the heart&#xD;
      (this will be measured preload in this trial by MRI assessed end diastolic volume). The fact&#xD;
      that dapagliflozin reduces both preload and afterload on the heart makes it uniquely&#xD;
      promising as a way to reducing future CV events in patients with diabetes and, here, in&#xD;
      reducing LV hypertrophy. Thus, dapagliflozin should regress LVH in patients with diabetes&#xD;
      because it is unique in reducing the four main causes of LVH: glycaemia/insulin resistance,&#xD;
      weight, preload and blood pressure. No other anti-diabetic medication alters even three of&#xD;
      these. Even metformin only alters two since it does not change blood pressure. All other&#xD;
      diabetic medications only reduce one (glycaemia) of these mediators of LVH. This may be why&#xD;
      other new anti-glycaemic agents have failed to reduce CV events. In this trial, it is&#xD;
      proposed to trial whether dapagliflozin causes regression of the independent cardiac risk&#xD;
      factor of LVH in diabetic participants on optimal current evidence based therapy.&#xD;
&#xD;
      Original Hypothesis&#xD;
&#xD;
      Dapagliflozin will regress LVH in normotensive participants with type 2 diabetes.&#xD;
&#xD;
      RATIONALE FOR TRIAL&#xD;
&#xD;
      Cardiac MRI will be used to assess whether Dapagliflozin regresses LV mass more than placebo&#xD;
      does over a one year treatment period. If it does, this would strongly suggest that&#xD;
      Dapagliflozin will reduce CV events especially in the 44% of patients with type 2 diabetes&#xD;
      who have LVH despite a controlled blood pressure.&#xD;
&#xD;
      All studies examining LVH regression require to be parallel group studies as effects on LV&#xD;
      mass take 6-12 months to occur. Hence this is a parallel group, one year trial of the active&#xD;
      drug vs. placebo.&#xD;
&#xD;
      The issue of what dapagliflozin does to CV events in diabetes is a hot topic. Most new&#xD;
      antidiabetic drugs have been neutral or harmful but, judging by its pharmacological effects,&#xD;
      it is quite possible that dapagliflozin might reduce CV events. A large ongoing trial&#xD;
      (Dapagliflozin Effect on CardiovascuLAR Events - Thrombolysis in Myocardial Infarction&#xD;
      (DECLARE - TIMI)) is just beginning to look at this. Why therefore do we also need to trial&#xD;
      the effects of dapagliflozin on LV mass in those with LVH? If DECLARE-TIMI shows clearly that&#xD;
      dapagliflozin reduces CV events, then our trial will have revealed a possible contributing&#xD;
      mechanism to the reduced CV events i.e. LVH regression (patients in DECLARE-TIMI will not&#xD;
      receive echocardiography so that subgroup analysis will not be able to answer this question&#xD;
      and electrocardiograms are useless at identifying LVH. Furthermore, the accuracy of MRI over&#xD;
      echo is so great that echo studies of LVH regression should no longer be considered&#xD;
      reliable).&#xD;
&#xD;
      In other words, large mega-trials like DECLARE-TIMI are very valuable, but parallel smaller&#xD;
      mechanistic studies like this can enhance their value by helping to explain the mechanisms&#xD;
      producing the mega-trial results and/or helping to identify a subgroup who get a particular&#xD;
      benefit meaning that the drug becomes more cost effective in that subgroup. Overall, this&#xD;
      trial might, in conjunction with a mega-trial, help decide the course of future research&#xD;
      (should LVH be a favoured target?) and help decide how to apply the results of a mega-trial&#xD;
      in clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Actual">April 2, 2019</completion_date>
  <primary_completion_date type="Actual">March 14, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular (LV) Mass by Cardiac MRI at 52 weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>To see if Dapagliflozin reduces LV mass more than placebo in participants with type 2 diabetes and LV hypertrophy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24 hour blood pressure (BP) recording at 52 weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>To confirm expected effect of dapagliflozin on BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office blood pressure (BP) at 4, 17, 34 and 52 weeks</measure>
    <time_frame>Baseline, 4, 17, 34 and 52 weeks</time_frame>
    <description>To confirm expected effect of dapagliflozin on BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body mass index at 4, 17, 34 and 52 weeks</measure>
    <time_frame>Baseline 4, 17, 34 and 52 weeks</time_frame>
    <description>To confirm expected effect of dapagliflozin on body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist/hip ratio at 4, 17, 34 and 52 weeks</measure>
    <time_frame>Baseline 4, 17, 34 and 52 weeks</time_frame>
    <description>To confirm expected effect of dapagliflozin on waist/hip ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference at 4, 17, 34 and 52 weeks</measure>
    <time_frame>Baseline 4, 17, 34 and 52 weeks</time_frame>
    <description>To confirm expected effect of dapagliflozin on waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral fat massed with Abdominal MRI at 52 weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>To assess the effect of dapagliflozin on visceral fat mass.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c at 4, 17, 34 and 52 weeks</measure>
    <time_frame>Baseline, 4, 17, 34 and 52 weeks</time_frame>
    <description>To assess the effects of dapagliflozin on HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events related to treatment</measure>
    <time_frame>4, 17, 34 and 52 weeks</time_frame>
    <description>Urinary symptoms and hypotensive symptoms will assess the tolerability of dapagliflozin in this patient group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal laboratory values</measure>
    <time_frame>4, 17, 34 and 52 weeks</time_frame>
    <description>Liver function tests will assess the tolerability of dapagliflozin in this patient group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin Resistance Index (FIRI) at 4, 17, 34 and 52 weeks</measure>
    <time_frame>Baseline, 4, 17, 34 and 52 weeks</time_frame>
    <description>To assess the effects of dapagliflozin on FIRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in B-type Natriuretic Peptide (BNP) at 4, 17, 34 and 52 weeks</measure>
    <time_frame>Baseline, 4, 17, 34 and 52 weeks</time_frame>
    <description>To assess the effects of dapagliflozin on BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in uric acid at 4, 17, 34 and 52 weeks</measure>
    <time_frame>Baseline, 4, 17, 34 and 52 weeks</time_frame>
    <description>To assess the effects of dapagliflozin on uric acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic function and global longitudinal strain</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>To assess the effect of dapagliflozin on left ventricular diastolic function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin 10mg once daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 10mg once daily for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>SGLT2 inhibitor</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent before any trial specific procedures.&#xD;
&#xD;
          2. Diagnosed with type 2 diabetes mellitus based on the current American Diabetes&#xD;
             Association guidelines.&#xD;
&#xD;
          3. Aged &gt;18 and &lt;80 years&#xD;
&#xD;
          4. Body Mass Index â‰¥23&#xD;
&#xD;
          5. HbA1c 48-85mmol/mol (last known result within in the previous 6 months)&#xD;
&#xD;
          6. Blood pressure &lt;145/90mmHg. Office BP at screening visit will be used however if this&#xD;
             is above the inclusion criteria then the 24 hour or 16 hour recording at screening&#xD;
             visit will be used to confirm that in the opinion of the PI the BP is adequately&#xD;
             controlled.&#xD;
&#xD;
          7. Echocardiographic left ventricular (LV) hypertrophy (defined as an LV mass index of&#xD;
             &gt;115g/m2 for men and &gt;95g/m2 for women indexed to body surface area or &gt;48g/m2.7 or&#xD;
             &gt;44g/m2.7 when indexed to height) within the previous 6 months.&#xD;
&#xD;
          8. Women of childbearing potential must agree to take precautions to avoid pregnancy&#xD;
             throughout the trial and for 4 weeks after intake of the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. 1. Any condition that in the opinion of the investigator may render the participant&#xD;
             unable to complete the trial including non CV disease (e.g. active malignancy).&#xD;
&#xD;
          2. Participants with type 1 diabetes mellitus&#xD;
&#xD;
          3. Participants who have previously had an episode of diabetic ketoacidosis.&#xD;
&#xD;
          4. Serum Potassium or Sodium results outwith the normal range&#xD;
&#xD;
          5. Diagnosis of clinical heart failure&#xD;
&#xD;
          6. History of human immunodeficiency virus&#xD;
&#xD;
          7. LV systolic dysfunction (LVEF &lt;45%) (last known result within in the previous 6&#xD;
             months)&#xD;
&#xD;
          8. eGFR &lt;45ml/min (last known result within in the previous month)&#xD;
&#xD;
          9. Known liver function tests &gt;3 times upper limit of normal (based on last measures and&#xD;
             documented laboratory measurement in the previous 6 months)&#xD;
&#xD;
         10. Body weight &gt;150Kg (unable to fit into a MRI scanner)&#xD;
&#xD;
         11. Contraindications to MRI (e.g. claustrophobia, metal implants, penetrative eye injury&#xD;
             or exposure to metal fragments in eye requiring medical attention)&#xD;
&#xD;
         12. Past or current treatment with any SGLT2 inhibitor&#xD;
&#xD;
         13. Allergy to any SGLT2 inhibitor or lactose or galactose intolerance&#xD;
&#xD;
         14. Current treatment with loop diuretic&#xD;
&#xD;
         15. Currently receiving long term (&gt;30 consecutive days) treatment with an oral steroid&#xD;
&#xD;
         16. Pregnant or breast feeding participants&#xD;
&#xD;
         17. Involvement in the planning and/or conduct of the trial (applies to Astra Zeneca or&#xD;
             representative staff and/or staff at the trial site).&#xD;
&#xD;
         18. Participation in another interventional study (other than observational trials and&#xD;
             registries) within 30 days before visit 1.&#xD;
&#xD;
         19. Individuals considered at risk for poor protocol or medication compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Struthers, MD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chim Lang, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Graeme Houston, FRCR, MBBCh</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rory McCrimmon, MBChB, MRCP</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2016</study_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Left Ventricular Hypertrophy</keyword>
  <keyword>Dapagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

